Article Versions Notes

Rouland A, Gautier T, Denimal D, Duvillard L, Simoneau I, Rageot D, Vergès B, Bouillet B. The Endogenous Inhibitor of CETP, apoC1, Remains Ineffective In Vivo after Correction of Hyperglycemia in People with Type 1 Diabetes. Metabolites. 2024; 14(9):487. https://doi.org/10.3390/metabo14090487

Rouland, Alexia, Thomas Gautier, Damien Denimal, Laurence Duvillard, Isabelle Simoneau, David Rageot, Bruno Vergès, and Benjamin Bouillet. 2024. "The Endogenous Inhibitor of CETP, apoC1, Remains Ineffective In Vivo after Correction of Hyperglycemia in People with Type 1 Diabetes" Metabolites 14, no. 9: 487. https://doi.org/10.3390/metabo14090487

Rouland, A., Gautier, T., Denimal, D., Duvillard, L., Simoneau, I., Rageot, D., Vergès, B., & Bouillet, B. (2024). The Endogenous Inhibitor of CETP, apoC1, Remains Ineffective In Vivo after Correction of Hyperglycemia in People with Type 1 Diabetes. Metabolites, 14(9), 487. https://doi.org/10.3390/metabo14090487